First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
- 1.2k Downloads
The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). Here, we evaluated duration of response (DoR), tumor shrinkage, PFS by treatment-free interval (TFI), and health-related quality of life (HRQoL).
Postmenopausal women (N = 668) with HR+ , HER2− ABC and no prior systemic therapy for ABC were randomized to RIB (600 mg/day; 3 weeks on/1 week off) plus LET (2.5 mg/day; continuous) or placebo (PBO) plus LET. Primary end point was PFS; HRQoL was the secondary end point; DoR was exploratory end point and PFS by TFI was post hoc analysis.
Of 501 pts with measurable disease and confirmed complete or partial response, median DoR was 26.7 months (95% CI, 24.0–NR) in the RIB arm versus 18.6 months (95% CI, 14.8–23.1) in the PBO arm. At 8 weeks, more pts in the RIB arm (32%) versus the PBO arm (17%) experienced best percentage change ≥ 60%. The average pain reduction was greater in the RIB arm (26%) versus the PBO arm (15%). PFS benefit was seen with RIB vs PBO, irrespective of TFI.
RIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2− ABC.
KeywordsRibociclib Advanced breast cancer MONALEESA-2 CDK4/6
We thank the patients who participated in this trial and their families, as well as staff members at individual trial centers who provided support; Avinash Yerramsetti and Amol Hosing (Novartis Healthcare Pvt Ltd) for providing medical editorial assistance with this manuscript. Ribociclib was discovered by Novartis Institutes for BioMedical Research in collaboration with Astex Pharmaceuticals.
The study was initiated, funded, and sponsored by Novartis Pharmaceuticals Corporation. The study was designed by the investigators and the sponsor. Design and conduct of the study was undertaken by the sponsor in collaboration with investigators. The study investigators and their respective research teams collected the data; Novartis Pharmaceuticals Corporation compiled the data for summation and analysis. All authors were responsible for data interpretation. The article was prepared by Dr Janni in conjunction with all the authors, including employees of the sponsor. The corresponding author had final responsibility for the decision to submit the manuscript for publication.
Compliance with ethical standards
Conflict of interest
Dr. Janni reports grants and personal fees from Novartis during the conduct of the study and outside the submitted work. Dr. Alba reports advisory board fees from Roche, Pfizer, and Novartis outside the submitted work. Dr. Bachelot reports personal fees from AstraZeneca, Roche, Novartis, and Pfizer; research grants from Roche, Novartis, and Pfizer outside the submitted work. Dr. Esteva reports consulting fee and research funding to his institution. Dr. Pluard reports advisory board fees from Novartis. Mr. Sutradhar is an employee of Novartis Pharmaceutical Corporation. Dr. Miller is employee of Novartis Pharmaceutical Corporation and hold Novartis stock options. Prof. Campone reports fees for advisory boards from Novartis, during the conduct of the study; and fees for advisory boards from Lilly, Sanofi, Pfizer, and AstraZeneca outside the submitted work. Dr. Diab, Dr. Gil, Dr. Beck, Ryvo, Dr. Tsai, Dr. Aunon, Dr. Kral, Dr. Ward, and Dr. Richards have nothing to disclose.
- 3.Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, van’t Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer B (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871–1888. https://doi.org/10.1093/annonc/mdu385 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Breast Cancer version 2.2017Google Scholar
- 8.Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, Gonzalez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL (2011) ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1:338–351. https://doi.org/10.1158/2159-8290.CD-11-0101 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425–439. https://doi.org/10.1016/s1470-2045(15)00613-0 CrossRefPubMedGoogle Scholar
- 11.Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25–35. https://doi.org/10.1016/s1470-2045(14)71159-3 CrossRefPubMedGoogle Scholar
- 12.Finn RS, Martin M, Rugo HS, Jones SE, Im S-A, Gelmon KA, Harbeck N, Lipatov ON, Walshe JM, Moulder SL, Gauthier ER, Lu D, Randolph S, Diéras V, Slamon DJ (2016) PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2− advanced breast cancer (ABC). J Clin Oncol 34:507. https://doi.org/10.1200/JCO.2016.34.15_suppl.507 CrossRefGoogle Scholar
- 13.Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M (2015) Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med 373:209–219. https://doi.org/10.1056/nejmoa1505270 CrossRefPubMedGoogle Scholar
- 14.Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, Parasuraman S, Howard S, Keen N, Sellers W, Brain C (2013) Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6− reactivating Rb in cancer. Molecular Cancer Therapeutics 12:PR02-PR02. https://doi.org/10.1158/1535-7163.targ-13-pr02
- 15.O’Brien NA, Tomaso ED, Ayala R, Tong L, Issakhanian S, Linnartz R, Finn RS, Hirawat S, Slamon DJ (2014) Abstract 4756: in vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. Cancer Res 74:4756. https://doi.org/10.1158/1538-7445.am2014-4756 CrossRefGoogle Scholar
- 16.Juric D, Munster PN, Campone M, Ismail-Khan R, García-Estevez L, Hamilton EP, Becerra C, Boer RHD, Hui R, Goncalves A, Wang Y, Dhuria SV, Kalimi GH, Lorenc KCR, Mayer IA (2016) Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2−) advanced breast cancer (aBC): phase Ib safety, preliminary efficacy and molecular analysis. J Clin Oncol 34:568. https://doi.org/10.1200/JCO.2016.34.15_suppl.568 CrossRefGoogle Scholar
- 17.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–1748. https://doi.org/10.1056/NEJMoa1609709 CrossRefPubMedGoogle Scholar
- 18.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte PF, Arteaga CL, Cameron DA, Xuan F, Miller MK, Germa C, Hirawat S, O’Shaughnessy J (2017) Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2−), advanced breast cancer (ABC). J Clin Oncol 35:1038. https://doi.org/10.1200/JCO.2017.35.15_suppl.1038 CrossRefGoogle Scholar
- 20.Gregorc V, Ghio D, Sallemi C, Bulotta A, Rossoni G, Viganò MG, Fontana F, Rossoni G, Colombi S, Lambiase A, Bordignon C (2015) Treatment-free interval (TFI) after first-line therapy as a prognostic and predictive factor in malignant pleural mesothelioma (MPM): findings from the NGR015 phase III trial with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC. J Clin Oncol 33:7557. https://doi.org/10.1200/jco.2015.33.15_suppl.7557 CrossRefGoogle Scholar
- 21.Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017) MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. https://doi.org/10.1200/jco.2017.75.6155 CrossRefPubMedGoogle Scholar
- 22.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMedGoogle Scholar
- 24.Verma S, O’Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Manson S, Sutradhar SC, Monaco M, Janni W (2017) Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib + letrozole: results from MONALEESA-2. J Clin Oncol 35:1020. https://doi.org/10.1200/JCO.2017.35.15_suppl.1020 CrossRefGoogle Scholar
- 25.Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ (2016) Palbociclib and Letrozole in advanced breast cancer. N Engl J Med 375:1925–1936. https://doi.org/10.1056/NEJMoa1607303 CrossRefPubMedGoogle Scholar
- 27.Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, André F, Loi S, Verma S, Iwata H, Bhattacharyya H, Puyana Theall K, Bartlett CH, Loibl S (2016) Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 27:1047–1054. https://doi.org/10.1093/annonc/mdw139 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Boye M, Houghton K, Stull DE, Ainsworth C, Price GL (2017) Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: data analysis from a phase II study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer after chemotherapy for metastatic disease—MONARCH 1. J Clin Oncol 35:1060. https://doi.org/10.1200/JCO.2017.35.15_suppl.1060 CrossRefGoogle Scholar